Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease
Conclusion
This study demonstrated that the effect of a cardiovascular polypill on risk factor levels is modified by the level of these risk factors. Groups defined by baseline LDL-cholesterol or systolic BP had large differences in risk factor reductions but only moderate differences in estimated cardiovascular relative risk reduction, suggesting also that patients with mildly increased risk factor levels but an overall raised cardiovascular risk benefit from being treated with a polypill.
Source: European Journal of Preventive Cardiology - Category: Cardiology Authors: Lafeber, M., Webster, R., Visseren, F. L., Bots, M. L., Grobbee, D. E., Spiering, W., Rodgers, A., on behalf of the Programme to Improve Life and Longevity (PILL) Collaborative Group Tags: Original scientific paper Source Type: research
More News: Aspirin | Cardiology | Cardiovascular | Cholesterol | Heart | Hydrochlorothiazide | Lisinopril | Simvastatin | Statin Therapy | Study | Zocor